Overview

• GSK has finalized the acquisition of efimosfermin, a once-monthly injectable therapy for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease.
• The $1.2 billion upfront payment to Boston Pharmaceuticals could rise to $2 billion with milestone achievements, with Novartis entitled to royalties as the drug's original licensor.
• Efimosfermin is ready to enter Phase 3 clinical trials and aims to treat and prevent the progression of liver fibrosis, a leading cause of liver transplants.
• This acquisition aligns with GSK’s strategy of bolstering its biopharma pipeline through targeted deals, as it aims to surpass £40 billion in revenue by 2031.
• Liver disease treatments are drawing significant interest from major pharmaceutical companies due to the lack of effective therapies and the high healthcare costs associated with advanced liver conditions.